Timothy E. G. Krueger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Timothy E. G. Krueger has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- William Nathaniel Brennen
Department of Oncology, Johns Hopkins School of Medicine; Baltimore, Maryland
3 shared publications - Amber E. de Groot
Arcus Biosciences, Hayward, California. 1
2 shared publications - Kayla V. Myers
Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA
2 shared publications - Sarah R. Amend
Cancer Ecology Center, The Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
2 shared publications Alexandria Brame
Department of Urology, James Buchanan Brady Urological Institute Johns Hopkins School of Medicine Baltimore Maryland USA
1 shared publicationAngelo M. De Marzo
Department of Urology, James Buchanan Brady Urological Institute Johns Hopkins School of Medicine Baltimore Maryland USA
1 shared publication
Latest Publications
- Open Access
- 5 May 2021
- Published by Wiley in The Prostate
- Vol. 81 (10) , 629-647
Characterization of tumor‐associated macrophages in prostate cancer transgenic mouse models
Background: Tumor‐associated macrophages (TAMs) are critical components of the tumor microenvironment (TME) in prostate cancer. Commonly used orthotopic models do not accurately reflect the complete TME of a human patient or the natural initiation and progression of a tumor. Therefore, genetically engineered mouse models are essential for studying the TME as well as advancing TAM‐targeted therapies. Two common transgenic (TG) models of prostate cancer are Hi‐Myc and transgenic adenocarcinoma of the mouse prostate (TRAMP), but the TME and TAM characteristics of these models have not been well characterized.Methods: To advance the Hi‐Myc and TRAMP models as tools for TAM studies, macrophage infiltration and characteristics were assessed using histopathologic, flow cytometric, and expression analyses in these models at various timepoints during tumor development and progression.Results: In both Hi‐Myc and TRAMP models, macrophages adopt a more pro‐tumor phenotype in higher histological grade tumors and in older prostate tissue. However, the Hi‐Myc and TRAMP prostates differ in their macrophage density, with Hi‐Myc tumors exhibiting increased macrophage density and TRAMP tumors exhibiting decreased macrophage density compared to age‐matched wild type mice.Conclusions: The macrophage density and the adenocarcinoma cancer subtype of Hi‐Myc appear to better mirror patient tumors, suggesting that the Hi‐Myc model is the more appropriate in vivo TG model for studying TAMs and TME‐targeted therapies.
- 5 May 2021
- Published by Wiley in The Prostate
- Vol. 81 (10) , 629-647
Open AccessCharacterization of tumor‐associated macrophages in prostate cancer transgenic mouse models
Background: Tumor‐associated macrophages (TAMs) are critical components of the tumor microenvironment (TME) in prostate cancer. Commonly used orthotopic models do not accurately reflect the complete TME of a human patient or the natural initiation and progression of a tumor. Therefore, genetically engineered mouse models are essential for studying the TME as well as advancing TAM‐targeted therapies. Two common transgenic (TG) models of prostate cancer are Hi‐Myc and transgenic adenocarcinoma of the mouse prostate (TRAMP), but the TME and TAM characteristics of these models have not been well characterized.Methods: To advance the Hi‐Myc and TRAMP models as tools for TAM studies, macrophage infiltration and characteristics were assessed using histopathologic, flow cytometric, and expression analyses in these models at various timepoints during tumor development and progression.Results: In both Hi‐Myc and TRAMP models, macrophages adopt a more pro‐tumor phenotype in higher histological grade tumors and in older prostate tissue. However, the Hi‐Myc and TRAMP prostates differ in their macrophage density, with Hi‐Myc tumors exhibiting increased macrophage density and TRAMP tumors exhibiting decreased macrophage density compared to age‐matched wild type mice.Conclusions: The macrophage density and the adenocarcinoma cancer subtype of Hi‐Myc appear to better mirror patient tumors, suggesting that the Hi‐Myc model is the more appropriate in vivo TG model for studying TAMs and TME‐targeted therapies.
- 5 November 2020
- Published by Taylor & Francis in Immunotherapy
- Vol. 13 (2) , 155-175
Overcoming Stromal Barriers to Immuno-Oncological Responses via Fibroblast Activation Protein-Targeted Therapy
The tumor microenvironment contributes to disease progression through multiple mechanisms, including immune suppression mediated in part by fibroblast activation protein (FAP)-expressing cells. Herein, a review of FAP biology is presented, supplemented with primary data. This includes FAP expression in prostate cancer and activation of latent reservoirs of TGF-β and VEGF to produce a positive feedback loop. This collectively suggests a normal wound repair process subverted during cancer pathophysiology. There has been immense interest in targeting FAP for diagnostic, monitoring and therapeutic purposes. Until recently, this development has outpaced an understanding of the biology; impeding optimal translation into the clinic. A summary of these applications is provided with an emphasis on eliminating tumor-infiltrating FAP-positive cells to overcome stromal barriers to immuno-oncological responses.
- 5 November 2020
- Published by Taylor & Francis in Immunotherapy
- Vol. 13 (2) , 155-175
Overcoming Stromal Barriers to Immuno-Oncological Responses via Fibroblast Activation Protein-Targeted Therapy
The tumor microenvironment contributes to disease progression through multiple mechanisms, including immune suppression mediated in part by fibroblast activation protein (FAP)-expressing cells. Herein, a review of FAP biology is presented, supplemented with primary data. This includes FAP expression in prostate cancer and activation of latent reservoirs of TGF-β and VEGF to produce a positive feedback loop. This collectively suggests a normal wound repair process subverted during cancer pathophysiology. There has been immense interest in targeting FAP for diagnostic, monitoring and therapeutic purposes. Until recently, this development has outpaced an understanding of the biology; impeding optimal translation into the clinic. A summary of these applications is provided with an emphasis on eliminating tumor-infiltrating FAP-positive cells to overcome stromal barriers to immuno-oncological responses.